Company: MBVI
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001213900-25-071471
Chunk: 9

Company: M3-Brigade Acquisition VI Corp.
Filing Date: 2025-08-04
Form: S-1
Chunk 9
---
option is exercised in full, payable to Cantor Fitzgerald & Co. for deferred underwriting commissions to be deposited into a trust account located in the United States and released to Cantor Fitzgerald & Co. for its own account only upon the completion of an initial business combination. See also “Underwriting” for a description of compensation and other items of value payable to the underwriters. Of the proceeds we receive from this offering and the sale of the private placement warrants described in this prospectus, $ 300million, or $ 345million if the underwriter’s overallotment option is exercised in full ($ 10.00per unit in either case), will be placed into a U.S. -basedtrust account with Continental Stock Transfer & Trust Company acting as trustee. Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of this offering, assuming no value is ascribed to the warrants included in the units. Further, the Class A ordinary shares issuable in connection with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti -dilutionrights of our founder shares that may result in an issuance of Class A ordinary shares on a greater than one -to-onebasis upon conversion. If we raise additional funds through equity or convertible debt issuances, our public shareholders may also suffer significant dilution. This dilution would increase to the extent that the anti -dilutionprovision of the founder shares results in the issuance of Class A shares on a greater than one -to-onebasis upon conversion of the founder shares at the time of our initial business combination. The compensation to be paid to the sponsor, Class A ordinary shares issuable in connection with the conversion of the founder shares, and securities to be issued to the sponsor in the private placement may result in a material dilution of our public shareholders’ equity interests. Our public shareholders may also experience material dilution from the exercise of the private placement warrants to be purchased simultaneously with the closing of this offering, which private placement warrants may be exercised on a cashless basis along with the public warrants under the circumstances specified in the warrant agreement. Additionally, our public shareholders may experience material dilution if the $1,500,000 in working capital loans is advanced by our sponsor and our sponsor elects to convert the working capital loans into up to an additional 1,500,000 private placement warrants, which private placement warrants may result in material dilution to our public shareholders